BioSpace News Archive

Biotech Bay

Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial

Rigel Pharmaceuticals, Inc. today announced that fostamatinib, the Company’s novel oral spleen tyrosine kinase (SYK) inhibitor, has been selected for a National Institutes of Health ACTIV-4 trial.

June 29, 2021
·
8 min read
Business

Encompass Health announces date of 2021 second quarter conference call

Encompass Health Corp. (NYSE: EHC) today announced it will report results for its second quarter ended June 30, 2021 , after the market closes on July 27, 2021 .

June 29, 2021
·
1 min read
Genetown

Paragonix Technologies Announces GUARDIAN-LUNG, the First Global Registry for Studying Donor Lung Preservation

Paragonix Technologies, Inc. today announces the launch of its clinical global registry, GUARDIAN-LUNG (Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs).

June 29, 2021
·
5 min read
Biotech Beach

Development of BioVie’s NE3107 Asset Featured by the American Diabetes AssociationNE3107 Featured in the ADA’s Thought Leadership Film Series at Annual Scientific Session

BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, announced today that a video documentary detailing the development history of the Company’s newly acquired NE3107 asset will be featured in the American Diabetes Association’s Thought Leadership Film Series on ADA TV,

June 29, 2021
·
4 min read
Drug Development

Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate CancerNext-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index

Propella Therapeutics, Inc. today announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.

June 29, 2021
·
3 min read
FDA

TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma

TRACON Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to envafolimab

June 29, 2021
·
8 min read
Biotech Beach

Thermo Fisher Scientific Launches Collection Kit to Streamline Saliva Testing

To support large-scale research and surveillance programs, Thermo Fisher Scientific today introduced the Thermo Scientific SpeciMAX Saliva Collection Kit*.

June 29, 2021
·
3 min read
Drug Development

Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy

Trial to evaluate safety and efficacy of pitolisant for excessive daytime sleepiness and other non-muscular symptoms in adult patients with type 1 myotonic dystrophy

June 29, 2021
·
8 min read
Lone Star Bio

Babson Diagnostics Raises $31 Million in Series B Funding to Drive Retailization of Customer-First, Convenient, and Highly Accessible Diagnostic Blood Testing

Babson Diagnostics today announced the closing of $31 million in an oversubscribed Series B funding round, led by Emerald Development Managers , with full participation by existing investors Siemens Healthineers, Prism Ventures, and Lago Consulting Group.

June 29, 2021
·
4 min read
Biotech Bay

Pear Therapeutics Announces First Participant Enrolled in National Institutes of Health Clinical Trial Investigating Combinations of Pharmacological and Behavioral Interventions to Treat Opioid Use Disorder

Pear Therapeutics, Inc. today announced the first participant enrolled in the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN)-0100 study on optimizing retention, duration, and discontinuation strategies for pharmacotherapy treatment of opioid use disorder (OUD), using Pear’s prescription digital therapeutic (PDT) reSET-O®.

June 29, 2021
·
6 min read